Literature DB >> 29446222

Engineering controls in veterinary oncology: A survey of 148 ACVIM board-certified oncologists and environmental surveillance in 20 specialty hospitals.

K Alexander1, N Northrup1, D Clarke1, H Lindell1, T Laver1.   

Abstract

Engineering controls (EC, facility and equipment barriers between hazards and people) are used to avoid exposure to chemotherapy drugs. In this study, American College of Veterinary Internal Medicine board-certified veterinary oncologists were surveyed about their use of containment primary EC (C-PEC) and supplemental EC (closed system transfer devices, CSTD). The survey was completed by 148 (38%) of practicing diplomates. All used EC. Both C-PEC and CSTD were used at 92% of hospitals; however, US Pharmacopoeial Convention Chapter <800> (USP <800>) standards were met at only 19% of hospitals and oncologists did not know the type of C-PEC at 18% of hospitals. Next, surface contamination and EC use were assessed with environmental surveillance for carboplatin, cyclophosphamide, doxorubicin, and vincristine in 20 veterinary specialty hospitals using a commercially available kit. No contamination with carboplatin, doxorubicin, or vincristine was detected, however, there was contamination with cyclophosphamide at 4 hospitals. Based on this study, most veterinary oncologists use C-PEC and CSTD, but few meet USP <800> standards. Current measures appear effective for preventing contamination with IV drugs, but additional measures are needed for oral drugs.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  USP <800>; chemotherapy; safety

Mesh:

Substances:

Year:  2018        PMID: 29446222     DOI: 10.1111/vco.12390

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  1 in total

1.  Efficiency of four solutions in removing 23 conventional antineoplastic drugs from contaminated surfaces.

Authors:  Nicolas Simon; Nicolas Guichard; Pascal Odou; Bertrand Decaudin; Pascal Bonnabry; Sandrine Fleury-Souverain
Journal:  PLoS One       Date:  2020-06-22       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.